China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
SYDNEY, Australia, Aug. 20, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that Grant Chamberlain will join the Board as a Non-Executive Director with immediate effect.
Mr Chamberlain brings extensive corporate finance and capital markets experience to Prima’s Board. Formerly Head of Mergers & Acquisitions and Financial Sponsors for Bank of America Merrill Lynch in Australia, Mr Chamberlain has more than twenty years experience in investment banking including former positions at Deutsche Bank and Nomura. He has advised major Australian and international companies on strategy, mergers and acquisitions and capital markets transactions.
Prima BioMed Chair Lucy Turnbull said: “We are delighted to welcome Grant to the Prima Board. His Australian and international markets experience will be a valuable asset as we progress our clinical development programs and consolidate our global leadership in LAG-3.”
Grant Chamberlain, on his appointment said: “I am honoured to join Prima’s Board. I have tremendous respect for Lucy and her fellow Directors and I’m excited about the potential of Prima’s LAG-3 technology. I look forward to contributing to Prima’s future success.”
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
